Medicines Formulary

Medicines A–Z

S

Drug name	NICE TAs	Comments
Selegiline lyophisilate		For patients with swallowing difficulties only
Selenium capsules
Selenium injection
Selenium tablets
Selpercatinib (Retsevmo®)	TA760 - Selpercatinib for previously treated RET fusion-positive advanced non-small cell lung cancer TA911 - Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer
Selsun® shampoo application
Semaglutide (Wegovy®)	TA875 - Semaglutide for managing overweight and obesity	The use of semaglutide for this indication is restricted to prescribing in secondary care by a specialist multidisciplinary Tier 3 weight management service with a commercial agreement in place. Prescribe by brand (Wegovy®) to avoid patients inadvertently receiving a different product licensed for type 2 diabetes. The Wegovy® brand of semaglutide is not commercially available yet.
Semaglutide solution for injection (Ozempic®)
Semaglutide tablets (Rybelsus®) (GLP1s should all be prescribed by brand name)
Senna syrup

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.